ATOSAtossa GeneticsATOS info
$1.46info0.62%24h
Global rank17899
Market cap$182.82M
Change 7d6.50%
YTD Performance62.11%
SP500 benchmarkOutperform
P/E0
P/S0
Revenue$0
Earnings$0
Dividend yield-
Main Sector
Healthcare
Business data

    Atossa Genetics (ATOS) Stock Overview

    Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

    ATOS Stock Information

    Symbol
    ATOS
    Address
    107 Spring StreetSeattle, WA 98104United States
    Founded
    -
    Trading hours
    -
    Website
    https://atossatherapeutics.com
    Country
    πŸ‡ΊπŸ‡Έ United States
    Phone Number
    206 588 0256

    Atossa Genetics (ATOS) Price Chart

    -
    Value:-

    Atossa Genetics Overview: Key Details and Summary

    Stock data
    2024
    Change
    Price
    $1.46
    N/A
    Market Cap
    $182.82M
    N/A
    Shares Outstanding
    125.30M
    N/A
    Employees
    11.00
    N/A
    logo
    Facebook Icon
    Twitter Icon
    Linkedin Icon
    Β© 2024 Topstocks.org